FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2081246207> ?p ?o ?g. }

• W2081246207 endingPage "2567" @default.
• W2081246207 startingPage "2558" @default.
• W2081246207 abstract "We have developed a new method for assembling targeted nanoparticles that utilizes the complexation between targeting agents that contain boronic acids and polymer–drug conjugates that possess diols. Here, we report the first in vivo, antitumor results of a nanoparticle formed via this new assembly methodology. A nanoparticle consisting of a mucic acid polymer conjugate of camptothecin (CPT), MAP–CPT, and containing on average one Herceptin antibody is investigated in nude mice bearing HER2 overexpressing BT-474 human breast cancer tumors. Nontargeted MAP–CPT and antibody-containing MAP–CPT nanoparticles of ca. 30–40 nm diameter and slightly negative zeta potential show prolonged in vivo circulation and similar biodistributions after intravenous tail vein injections in mice. The maximum tolerated dose (MTD) of the nontargeted and Herceptin-containing MAP–CPT nanoparticles is found to be 10 and 8 mg of CPT/kg, respectively, in mice. Mice bearing BT-474 human breast tumors treated with nontargeted MAP–CPT nanoparticles at 8 mg of CPT/kg show significant tumor growth inhibition (mean tumor volume of 63 mm3) when compared to irinotecan at 80 mg/kg (mean tumor volume of 575 mm3) and CPT at 8 mg/kg (mean tumor volume of 808 mm3) at the end of the study. Herceptin antibody treatment at 5.9 mg/kg results in complete tumor regressions in 5 out of 8 mice, with a mean tumor volume of 60 mm3 at the end of the study. Mice treated with MAP–CPT nanoparticles at 1 mg of CPT/kg do not show tumor inhibition. However, all mice receiving administrations of MAP–CPT nanoparticles (1 mg of CPT/kg) that contain on average a single Herceptin molecule per nanoparticle (5.9 mg of Herceptin equivalent/kg) show complete tumor regression by the end of the study. These results demonstrate that the antitumor efficacy of nanoparticles carrying anticancer drugs can be enhanced by incorporating on average a single antibody." @default.
• W2081246207 created "2016-06-24" @default.
• W2081246207 creator A5002864551 @default.
• W2081246207 creator A5010404427 @default.
• W2081246207 date "2013-05-29" @default.
• W2081246207 modified "2023-09-24" @default.
• W2081246207 title "Single-Antibody, Targeted Nanoparticle Delivery of Camptothecin" @default.
• W2081246207 cites W1536538430 @default.
• W2081246207 cites W1984007340 @default.
• W2081246207 cites W1986006871 @default.
• W2081246207 cites W2002516695 @default.
• W2081246207 cites W2006165138 @default.
• W2081246207 cites W2017231443 @default.
• W2081246207 cites W2021621347 @default.
• W2081246207 cites W2025989684 @default.
• W2081246207 cites W2026373761 @default.
• W2081246207 cites W2029839190 @default.
• W2081246207 cites W2043228552 @default.
• W2081246207 cites W2043371238 @default.
• W2081246207 cites W2045324973 @default.
• W2081246207 cites W2050316199 @default.
• W2081246207 cites W2050981032 @default.
• W2081246207 cites W2053894847 @default.
• W2081246207 cites W2074729580 @default.
• W2081246207 cites W2080592529 @default.
• W2081246207 cites W2086439640 @default.
• W2081246207 cites W2093614493 @default.
• W2081246207 cites W2095156669 @default.
• W2081246207 cites W2112055293 @default.
• W2081246207 cites W2112919362 @default.
• W2081246207 cites W2122328108 @default.
• W2081246207 cites W2139883287 @default.
• W2081246207 cites W2139891818 @default.
• W2081246207 cites W2141393790 @default.
• W2081246207 cites W2155256323 @default.
• W2081246207 cites W2156969927 @default.
• W2081246207 cites W2159459001 @default.
• W2081246207 cites W2159967578 @default.
• W2081246207 cites W2165164305 @default.
• W2081246207 cites W2171368669 @default.
• W2081246207 cites W2318605753 @default.
• W2081246207 cites W2322300598 @default.
• W2081246207 cites W4239989216 @default.
• W2081246207 cites W4252911605 @default.
• W2081246207 doi "https://doi.org/10.1021/mp300702x" @default.
• W2081246207 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3795804" @default.
• W2081246207 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23676007" @default.
• W2081246207 hasPublicationYear "2013" @default.
• W2081246207 type Work @default.
• W2081246207 sameAs 2081246207 @default.
• W2081246207 citedByCount "56" @default.
• W2081246207 countsByYear W20812462072013 @default.
• W2081246207 countsByYear W20812462072014 @default.
• W2081246207 countsByYear W20812462072015 @default.
• W2081246207 countsByYear W20812462072016 @default.
• W2081246207 countsByYear W20812462072017 @default.
• W2081246207 countsByYear W20812462072018 @default.
• W2081246207 countsByYear W20812462072019 @default.
• W2081246207 countsByYear W20812462072020 @default.
• W2081246207 countsByYear W20812462072021 @default.
• W2081246207 countsByYear W20812462072022 @default.
• W2081246207 countsByYear W20812462072023 @default.
• W2081246207 crossrefType "journal-article" @default.
• W2081246207 hasAuthorship W2081246207A5002864551 @default.
• W2081246207 hasAuthorship W2081246207A5010404427 @default.
• W2081246207 hasBestOaLocation W20812462072 @default.
• W2081246207 hasConcept C121608353 @default.
• W2081246207 hasConcept C126322002 @default.
• W2081246207 hasConcept C134306372 @default.
• W2081246207 hasConcept C150903083 @default.
• W2081246207 hasConcept C155672457 @default.
• W2081246207 hasConcept C159654299 @default.
• W2081246207 hasConcept C171250308 @default.
• W2081246207 hasConcept C185592680 @default.
• W2081246207 hasConcept C192562407 @default.
• W2081246207 hasConcept C197336794 @default.
• W2081246207 hasConcept C203014093 @default.
• W2081246207 hasConcept C207001950 @default.
• W2081246207 hasConcept C2779682216 @default.
• W2081246207 hasConcept C2780259306 @default.
• W2081246207 hasConcept C33923547 @default.
• W2081246207 hasConcept C526805850 @default.
• W2081246207 hasConcept C55493867 @default.
• W2081246207 hasConcept C71924100 @default.
• W2081246207 hasConcept C86803240 @default.
• W2081246207 hasConcept C98274493 @default.
• W2081246207 hasConceptScore W2081246207C121608353 @default.
• W2081246207 hasConceptScore W2081246207C126322002 @default.
• W2081246207 hasConceptScore W2081246207C134306372 @default.
• W2081246207 hasConceptScore W2081246207C150903083 @default.
• W2081246207 hasConceptScore W2081246207C155672457 @default.
• W2081246207 hasConceptScore W2081246207C159654299 @default.
• W2081246207 hasConceptScore W2081246207C171250308 @default.
• W2081246207 hasConceptScore W2081246207C185592680 @default.
• W2081246207 hasConceptScore W2081246207C192562407 @default.
• W2081246207 hasConceptScore W2081246207C197336794 @default.
• W2081246207 hasConceptScore W2081246207C203014093 @default.
• W2081246207 hasConceptScore W2081246207C207001950 @default.

• next